chidamide
Chidamide is an oral, selective histone deacetylase inhibitor (HDACi) from the benzamide class. It targets histone deacetylases HDAC1, HDAC2, HDAC3, and HDAC10, leading to increased acetylation of histones and other proteins. This epigenetic modulation alters gene expression and can induce cell-cycle arrest, differentiation, and apoptosis in cancer cells.
Clinically, chidamide is approved in mainland China for relapsed or refractory peripheral T-cell lymphoma (PTCL). It
Common adverse events observed in trials include hematologic abnormalities such as thrombocytopenia and neutropenia, as well
Chidamide is administered orally. Its regulatory status outside China varies, with ongoing research to define its